“On a positive note, sales of pharmaceuticals and medical lubricants increased in 2025 compared to 2024, by 15% and by 4%, respectively. The increase in medical lubricants was driven by greater demand from two of our large contract manufacturer customers in
| Contact: | |
| (631) 273-0900 | |
| dvigilante@u-g.com |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
| FINANCIAL RESULTS AS OF AND FOR THE YEARS ENDED STATEMENTS OF INCOME | ||||||||
| Years ended | ||||||||
| 2025 | 2024 | |||||||
| Net sales | $ | 10,545,468 | $ | 12,181,971 | ||||
| Costs and expenses: | ||||||||
| Cost of sales | 5,404,328 | 5,721,584 | ||||||
| Operating expenses | 2,434,148 | 2,356,819 | ||||||
| Research and development | 463,644 | 456,779 | ||||||
| Total costs and expenses | 8,302,120 | 8,535,182 | ||||||
| Income from operations | 2,243,348 | 3,646,789 | ||||||
| Other income: | ||||||||
| Investment income | 365,308 | 434,679 | ||||||
| Net gain on marketable securities | 34,359 | 26,989 | ||||||
| Total other income | 399,667 | 461,668 | ||||||
| Income before provision for income taxes | 2,643,015 | 4,108,457 | ||||||
| Provision for income taxes | 537,277 | 857,582 | ||||||
| Net income | $ | 2,105,738 | $ | 3,250,875 | ||||
| Earnings per common share (basic and diluted) | $ | 0.46 | $ | 0.71 | ||||
| Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | ||||||
| BALANCE SHEET DATA (condensed) | ||||||
| 2025 | 2024 | |||||
| Current assets: | $ | 12,201,397 | $ | 12,665,551 | ||
| Deferred tax asset, net | --- | 175,397 | ||||
| Property, plant, and equipment, net | 907,182 | 956,387 | ||||
| Total assets | 13,108,579 | 13,797,335 | ||||
| Current liabilities: | 1,669,321 | 1,914,469 | ||||
| Deferred tax liability, net | 207,246 | --- | ||||
| Total liabilities | 1,876,567 | 1,914,469 | ||||
| Stockholders’ equity | 11,232,012 | 11,882,866 | ||||
| Total liabilities and stockholders’ equity | $ | 13,108,579 | $ | 13,797,335 | ||
Source: 